A practical reference on nitric oxide system: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
If, for example, the Sun were replaced by a black hole of equal mass, the orbits of the planets would be essentially unaffected. Seasons are not caused by Earth being closer to the Sun in the summer than in the winter, but by the effects of Earth's 23.4-degree axial tilt. Each hemisphere is tilted towards the Sun in its respective summer, resulting in longer days and more perpendicular sunlight, with the opposite being true in the winter. Earth reaches the point in its orbit closest to the Sun in January, and it reaches the point farthest from the Sun in July, so the slight contribution of orbital eccentricity opposes the temperature trends of the seasons in the Northern Hemisphere. When a meteor or spacecraft enters the atmosphere, the heat of entry is not primarily caused by friction, but by adiabatic compression of air in front of the object. Egg balancing is possible on every day of the year, not just the vernal equinox. The Fisher Space Pen was not commissioned by NASA at a cost of millions of dollars, while the Soviets used pencils. Pencils posed a major risk to astronauts due to the release of substances such as shavings and pencil lead being a flight hazard. The pen was independently developed by Paul C. Fisher, founder of the Fisher Pen Company, with $1 million of his own funds (equivalent to $10 million in 2025). NASA tested and approved the pen for space use, then purchased 400 pens at $6 per pen (equivalent to $58 in 2025). The Soviet Union subsequently also purchased the Space Pen for its Soyuz spaceflights.
=== Veterinary === Deslorelin is used in veterinary medicine. One commercial form of deslorelin acetate is marketed by Peptech with the brand name Ovuplant. Another form is available in the United States, Sucromate Equine, which was FDA-approved for use in horses in November 2010. This is manufactured by Thorne BioScience LLC and was introduced to the United States market following the withdrawal of Ovuplant. The deslorelin products are currently approved for use in veterinary medicine and to promote ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion. Suprelorin is a slowly releasing deslorelin implant used for chemical castration of dogs and ferrets. It is marketed by Virbac. Deslorelin is also used to treat benign prostate hyperplasia in dogs. It is also used to treat pet parrots suffering from chronic egg laying behavior.
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
Sources: en.wikipedia.org
==== Sexist remarks ==== On several occasions throughout his third term, Lula, speaking extemporaneously, made comments which were largely regarded as sexist. In May 2024, while announcing measures for those affected by the floods in Rio Grande do Sul, he said that "a washing machine is a very important thing for women". The next day, at a ceremony for the delivery of housing units, he said he had spoken with a 27-year-old woman with 5 children, and asked "When are you going to close the gate, comrade?". At a meeting held in the Palácio do Planalto in July 2024, Lula commented on the result of a study that found that violence against women increases after football matches, concluding: "Unbelievable. If the guy is a Corinthians supporter, that's fine". At the event marking the 2 years since the January 8 attacks, he said "I am a lover of democracy, I am not even a husband, I am a lover of democracy, because, most of the time, lovers are more passionate about their lovers than about their wives". In March 2025, at a ceremony at the Palácio do Planalto, Lula said that he had appointed a "beautiful woman" as Minister of Institutional Relations to get closer to the presidents of the Senate and the Chamber. At the opening of the 29th International Construction and Architecture Fair, held in April 2025, Lula referred disparagingly to the managing director of the International Monetary Fund, Kristalina Georgieva, calling her "a little woman".
== Adverse events == The most common adverse events at the beginning of treatment are nausea and headache. More serious adverse events are peripheral neuropathy, which can occur in up to 33% of patients with advanced disease, oral ulcers, oesophageal ulcers and, rarely, pancreatitis.
Laser-based ambient ionization is a two-step process in which a pulsed laser is used to desorb or ablate material from a sample and the plume of material interacts with an electrospray or plasma to create ions. Lasers with ultraviolet and infrared wavelengths and nanosecond to femtosecond pulse widths have been used. Although atmospheric pressure MALDI is performed under ambient conditions, it is not generally considered to be an ambient mass spectrometry technique. Laser ablation was first coupled with mass spectrometry in the 1980s for the analysis of metals using laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS). The laser ablates the sample material that is introduced into an ICP to create atomic ions.
=== Thorium-231 === 231Th has 141 neutrons. It is the decay product of uranium-235. It is found in very small amounts on the earth and has a half-life of 25.52 hours. When it decays, it emits a beta ray and forms protactinium-231, with a decay energy of 0.39 MeV.
Sources: en.wikipedia.org
=== Russia === Russian authorities stated that Russia reacted to the numerous casualties among the South Ossetian civilian population caused by the Georgian attack. According to Russia, its aim was defence of Russian citizens and Russian peacekeepers in South Ossetia. According to the Russian military, the Russian peacekeepers in South Ossetia suffered casualties on August 8. Initially, Russia went as far as accusing Georgia of committing "genocide" against Ossetians. Defending Russia's decision to launch attack in uncontested Georgia, Russian Foreign Minister Sergey Lavrov said that Russian targeting of military infrastructure used for the Georgian attack was legally warranted. It was claimed that Georgia codenamed its attack Operation "Clear Field". Russia also claimed that Georgia was planning to launch a two-day Operation "Rock" to retake Abkhazia. Russia codenamed its military action "Operation to Force Georgia to Peace". The term "enforcing to peace" for describing the war against Georgia allegedly has been coined by General Anatoliy Nogovitsyn. Three years after the August War, President of Russia Dmitry Medvedev stated that NATO would have admitted Post-Soviet states if Russia had not invaded Georgia. "If you...had faltered back in 2008, the geopolitical situation would be different now," Medvedev declared at a Vladikavkaz military base. In response, the Georgian authorities claimed that Medvedev had admitted that Russia started the war with Georgia.
=== Sources of veterinarian stem cells === Veterinary applications of stem cell therapy as a means of tissue regeneration have been largely shaped by research that began with the use of adult-derived mesenchymal stem cells to treat animals with injuries or defects affecting bone, cartilage, ligaments and/or tendons. There are two main categories of stem cells used for treatments: allogeneic stem cells derived from a genetically different donor within the same species, and autologous mesenchymal stem cells, derived from the patient before use in various treatments. A third category, xenogenic stem cells, or stem cells derived from different species, are used primarily for research purposes, especially for human treatments.
The Tomorrow People (1970's TV Series), featured plot lines reflecting Cold War tension between the desire of British and Soviet militaries to use the Tomorrow People's fictional "special powers" of telepathy, teleportation, and telekinesis.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.